

FITC anti-mouse/human Ki-67

Catalog # / Size: 1356060 / 100 µg
1356055 / 25 µg

Clone: 11F6

Isotype: Rat IgG2b, κ


Immunogen: *E. coli* expressed, N-terminal His-Thioredoxin-tagged, partial mKi-67 (1816-2163 aa) recombinant protein.

Reactivity: Human, Mouse

Preparation: The antibody was purified by affinity chromatography and conjugated with FITC under optimal conditions. The solution is free of unconjugated FITC and unconjugated antibody.

Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.

Concentration: 0.5 mg/ml




Con A+IL-2-stimulated (3 days) C57BL/6 mouse splenocytes were fixed and permeabilized with 70% ethanol at -20°C for an hour and stained with Ki-67 (clone 11F6) FITC (filled histogram) or rat IgG2b, κ FITC isotype control (open histogram).

Applications:

Applications: Intracellular Flow Cytometry

Recommended Usage: Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.5 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.



Con A+IL-2-stimulated (3 days) C57BL/6 mouse splenocytes were fixed and permeabilized with 70% ethanol at -20°C for an hour and stained with DAPI and Ki-67 (clone 11F6) FITC (left), or rat IgG2b, κ FITC isotype control (right).

Description: The nuclear protein Ki-67 was first identified by the monoclonal antibody Ki-67, which was generated by immunizing mice with nuclei of the L428 Hodgkin lymphoma cell line. Ki-67 protein plays an essential role in ribosomal RNA transcription and cell proliferation. Expression of Ki-67 occurs during G1, S, G2, and M phase. While in G0 phase, the Ki-67 protein is not detectable. Ki-67 is strongly expressed in proliferating cells and has been reported as a prognostic marker in various tumors.

Antigen
References:

1. Starborg M, *et al.* 1996. *J. Cell. Sci.* 109:143.
2. Byeon IJ, *et al.* 2005. *Nat. Struct. Mol. Biol.* 12:987.
3. Yerushalmi R, *et al.* 2010. *Lancet. Oncol.* 11:174.
4. Beltrami AP, *et al.* 2001. *N. Engl. J. Med.* 344:1750.
5. Sachsenberg N, *et al.* 1998. *J. Exp. Med.* 187:1295.
6. Nagy Z, *et al.* 1997. *Acta. Neuropathol.* 93:294.